Table 2.
Signature Peptide Expression in Cell Lines
| Name | Cell Type | Actin 53 | BTK 526 | BTK 407 | BTK 545 | WASP 274 | WASP 14 | WASP 289 | CD3ε 197 | CD3ε 86 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Normalized to Cell Counta (x10^8) | Jurkat | T-cell leukemiac | 1.8 × 103 | NDb | ND | ND | 1.2 | 2.2 | 3.4 | 17.3 | 41.1 |
| HUT78 | T-cell lymphomac | 2.3 × 103 | ND | ND | ND | 11.0 | 12.8 | 12.8 | 5.0 | 14.6 | |
| Daudi | B-cell lymphomad | 3.0 × 103 | 9.0 | 6.3 | 5.3 | 10.9 | 15.1 | 17.7 | ND | ND | |
| WAS(−) BLCL | B lymphoblastse | 8.7 × 103 | 6.4 | 6.3 | 4.5 | ND | 0.5 | ND | ND | ND | |
| THP-1 | Myelomonocyticd | 1.8 × 104 | 62.7 | 7.7 | 3.3 | 3.7 | 15.3 | 71.4 | ND | ND | |
|
| |||||||||||
| Normalized to Actin (x10^3)a | Jurkat | T-cell leukemia | ND | ND | ND | 0.7 | 1.2 | 1.9 | 9.6 | 22.7 | |
| HUT78 | T-cell lymphoma | ND | ND | ND | 4.8 | 5.6 | 5.6 | 2.2 | 6.4 | ||
| Daudi | B-cell lymphoma | 3.0 | 2.1 | 1.8 | 3.6 | 5.0 | 5.9 | ND | ND | ||
| WAS(−) BLCL | B lymphoblasts | 0.7 | 0.7 | 0.5 | ND | 0.1 | ND | ND | ND | ||
| THP-1 | Myelomonocytic | 3.5 | 0.4 | 0.2 | 0.2 | 0.9 | 4.0 | ND | ND | ||
a
Relative ratio of peak area for signature peptide to peak area for isotopically labeled internal standard, normalized to cell count or actin concentration.
b
ND: Not detected.
c
Predicted phenotypes: T-cell lines: BTKnegWASP+CD3ε+, B-cell lines: BTK+WASP+CD3εneg, WAS(−) BLCL: BTK+WASPnegCD3εneg.